Centanafadine
Chemical compound
Nº Q27276010 ★★★
Rare · Savoirs
Centanafadine
Chemical compound
Centanafadine, sold under the brand name Simtriyo, is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD). It is taken orally. Common side effects of centanafadine include headache, appetite loss, insomnia, nausea, dry mouth, abdominal pain, and rash, among others.
Dernier prix
—
Prix plancher
—
Médiane 7 j
—
Ventes 30 j
0
Fourchette 30 j
—
En circulation
0
Cours
médiane
min – max
ventes
Aucune vente sur la période
Voir le tableau
| Date | médiane | Min | Max | ventes |
|---|
Historique des ventes
- Dernière vente
- —
- Moyenne 30 j
- —
- Plus bas 30 j
- —
- Plus haut 30 j
- —
- Ventes 7 j
- 0
- Ventes 30 j
- 0
Aucune vente pour l'instant.
Ventes anonymes : ni acheteur ni vendeur. Les chiffres ne comptent que les ventes entre joueurs.
Sur Wikipédia
Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.
Centanafadine, sold under the brand name Simtriyo, is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD). It is taken orally. Common side effects of centanafadine include headache, appetite loss, insomnia, nausea, dry mouth, abdominal pain, and rash, among others. It carries a boxed warning for suicidal ideation and behaviors in children and adolescents aged six years and older, as well as for potential abuse, misuse, and addiction. The drug is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with preference for norepinephrine and then dopamine over serotonin, and has stimulant effects. Centanafadine was approved for medical use in the United States in July 2026. Its scheduling as a controlled substance was pending as of August 2026.
Texte : Wikipédia en anglais, CC BY-SA 4.0. · Image : AlyInWikiWonderland (CC0) ·
